RPS6KB1 and cervical carcinoma: Our data also show that the treatment of cervical cancer cells with cisplatin induced activation of S6K1 and S6 (Fig. 6b), whose levels were already high in the cisplatin-resistant cervical cancer cell line (Fig. 6a).